Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Jumped Today While the Market Crashed

By Keith Speights - Updated Mar 18, 2020 at 3:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to be anticipating good news for the biotech.

What happened

Shares of Novavax (NVAX 11.12%) were jumping 10.4% higher as of 3:45 p.m. EDT on Wednesday after rising as much as 20.8% earlier in the day. How did Novavax stock perform so well while the overall stock market crashed yet again due to increasing worries about the coronavirus pandemic?

Investors appear to be optimistic about the prospects for Novavax to report positive results from its late-stage study of experimental flu vaccine NanoFlu. It also helps that the company is one of several drugmakers scrambling to test experimental COVID-19 vaccines.

Female healthcare professional holding a syringe and vaccine bottle

Image source: Getty Images.

So what

Any day now, Novavax could announce the results from its phase 3 clinical study evaluating nanoparticle-based flu vaccine NanoFlu. The vaccine demonstrated positive results in earlier clinical trials. NanoFlu holds the potential to be more effective than other flu vaccines that have already been approved.

The company also hopes to begin a phase 1 clinical study of its experimental COVID-19 vaccine in either May or June. Novavax is currently evaluating several nanoparticle vaccine candidates to select the most promising one to advance to clinical testing. 

Now what

If the late-stage results for NanoFlu are positive, Novavax will quickly file for U.S. regulatory approval of the vaccine. Until those results are announced, though, it's likely that this biotech stock will be highly volatile.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$57.15 (11.12%) $5.72

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.